101.82 USD
+0.44 (+0.43%)
101.82 USD
0 (0%)
EXAS gets a fundamental rating of 4 out of 10. The analysis compared the fundamentals against 530 industry peers in the Biotechnology industry. EXAS scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. EXAS has a correct valuation and a medium growth rate.
1. Profitability
1.1 Basic Checks
In the past year EXAS has reported negative net income.
In the past year EXAS had a positive cash flow from operations.
EXAS had negative earnings in each of the past 5 years.
The reported operating cash flow has been mixed in the past 5 years: EXAS reported negative operating cash flow in multiple years.
1.2 Ratios
EXAS has a better Return On Assets (-16.72%) than 78.76% of its industry peers.
EXAS has a Return On Equity of -39.44%. This is in the better half of the industry: EXAS outperforms 71.05% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -16.72% | ||
| ROE | -39.44% | ||
| ROIC | N/A |
ROA(3y)-10.17%
ROA(5y)-11.23%
ROE(3y)-23.27%
ROE(5y)-24.85%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
The Gross Margin of EXAS (67.37%) is better than 80.64% of its industry peers.
In the last couple of years the Gross Margin of EXAS has declined.
The Profit Margin and Operating Margin are not available for EXAS so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 67.37% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-2.06%
GM growth 5Y-1.57%
2. Health
2.1 Basic Checks
EXAS does not have a ROIC to compare to the WACC, probably because it is not profitable.
EXAS has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, EXAS has more shares outstanding
The debt/assets ratio for EXAS is higher compared to a year ago.
2.2 Solvency
EXAS has an Altman-Z score of 2.96. This is not the best score and indicates that EXAS is in the grey zone with still only limited risk for bankruptcy at the moment.
EXAS has a Altman-Z score of 2.96. This is in the better half of the industry: EXAS outperforms 68.42% of its industry peers.
The Debt to FCF ratio of EXAS is 9.47, which is on the high side as it means it would take EXAS, 9.47 years of fcf income to pay off all of its debts.
Looking at the Debt to FCF ratio, with a value of 9.47, EXAS belongs to the top of the industry, outperforming 90.23% of the companies in the same industry.
EXAS has a Debt/Equity ratio of 0.93. This is a neutral value indicating EXAS is somewhat dependend on debt financing.
EXAS has a worse Debt to Equity ratio (0.93) than 76.32% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.93 | ||
| Debt/FCF | 9.47 | ||
| Altman-Z | 2.96 |
ROIC/WACCN/A
WACC8.09%
2.3 Liquidity
A Current Ratio of 2.72 indicates that EXAS has no problem at all paying its short term obligations.
The Current ratio of EXAS (2.72) is worse than 68.42% of its industry peers.
EXAS has a Quick Ratio of 2.44. This indicates that EXAS is financially healthy and has no problem in meeting its short term obligations.
With a Quick ratio value of 2.44, EXAS is not doing good in the industry: 69.55% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.72 | ||
| Quick Ratio | 2.44 |
3. Growth
3.1 Past
EXAS shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -354.70%.
The Revenue has grown by 14.47% in the past year. This is quite good.
The Revenue has been growing by 25.78% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)-354.7%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%52.38%
Revenue 1Y (TTM)14.47%
Revenue growth 3Y16.01%
Revenue growth 5Y25.78%
Sales Q2Q%20.05%
3.2 Future
The Earnings Per Share is expected to grow by 21.50% on average over the next years. This is a very strong growth
Based on estimates for the next years, EXAS will show a quite strong growth in Revenue. The Revenue will grow by 11.01% on average per year.
EPS Next Y87.09%
EPS Next 2Y43.47%
EPS Next 3Y30.54%
EPS Next 5Y21.5%
Revenue Next Year17.56%
Revenue Next 2Y15.52%
Revenue Next 3Y14.38%
Revenue Next 5Y11.01%
3.3 Evolution
Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
4. Valuation
4.1 Price/Earnings Ratio
EXAS reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Based on the Price/Forward Earnings ratio of 313.03, the valuation of EXAS can be described as expensive.
Compared to the rest of the industry, the Price/Forward Earnings ratio of EXAS indicates a rather cheap valuation: EXAS is cheaper than 87.97% of the companies listed in the same industry.
When comparing the Price/Forward Earnings ratio of EXAS to the average of the S&P500 Index (23.84), we can say EXAS is valued expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 313.03 |
4.2 Price Multiples
Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of EXAS indicates a rather cheap valuation: EXAS is cheaper than 88.91% of the companies listed in the same industry.
91.92% of the companies in the same industry are more expensive than EXAS, based on the Price/Free Cash Flow ratio.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 78.2 | ||
| EV/EBITDA | 323.1 |
4.3 Compensation for Growth
The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
EXAS's earnings are expected to grow with 30.54% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y43.47%
EPS Next 3Y30.54%
5. Dividend
5.1 Amount
No dividends for EXAS!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
101.82
+0.44 (+0.43%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners94.55%
Inst Owner Change2.4%
Ins Owners0.85%
Ins Owner Change-0.68%
Market Cap19.32B
Revenue(TTM)3.08B
Net Income(TTM)-986.58M
Analysts68.28
Price Target100.65 (-1.15%)
Short Float %2.73%
Short Ratio0.85
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)27.24%
Min EPS beat(2)-40.06%
Max EPS beat(2)94.53%
EPS beat(4)1
Avg EPS beat(4)-344.13%
Min EPS beat(4)-1391.93%
Max EPS beat(4)94.53%
EPS beat(8)4
Avg EPS beat(8)-160.89%
EPS beat(12)8
Avg EPS beat(12)-92.72%
EPS beat(16)11
Avg EPS beat(16)-67.39%
Revenue beat(2)2
Avg Revenue beat(2)2.8%
Min Revenue beat(2)2.65%
Max Revenue beat(2)2.95%
Revenue beat(4)3
Avg Revenue beat(4)1.49%
Min Revenue beat(4)-0.27%
Max Revenue beat(4)2.95%
Revenue beat(8)3
Avg Revenue beat(8)0.13%
Revenue beat(12)6
Avg Revenue beat(12)1.15%
Revenue beat(16)10
Avg Revenue beat(16)1.59%
PT rev (1m)41.34%
PT rev (3m)53.54%
EPS NQ rev (1m)-5322.4%
EPS NQ rev (3m)-2135.44%
EPS NY rev (1m)-11.46%
EPS NY rev (3m)-20.43%
Revenue NQ rev (1m)0.36%
Revenue NQ rev (3m)4.15%
Revenue NY rev (1m)2.33%
Revenue NY rev (3m)2.33%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 313.03 | ||
| P/S | 6.27 | ||
| P/FCF | 78.2 | ||
| P/OCF | 49.95 | ||
| P/B | 7.72 | ||
| P/tB | N/A | ||
| EV/EBITDA | 323.1 |
EPS(TTM)-5.32
EYN/A
EPS(NY)0.33
Fwd EY0.32%
FCF(TTM)1.3
FCFY1.28%
OCF(TTM)2.04
OCFY2%
SpS16.24
BVpS13.18
TBVpS-4.26
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -16.72% | ||
| ROE | -39.44% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 67.37% | ||
| FCFM | 8.02% |
ROA(3y)-10.17%
ROA(5y)-11.23%
ROE(3y)-23.27%
ROE(5y)-24.85%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-2.06%
GM growth 5Y-1.57%
F-Score4
Asset Turnover0.52
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.93 | ||
| Debt/FCF | 9.47 | ||
| Debt/EBITDA | 36.88 | ||
| Cap/Depr | 63.99% | ||
| Cap/Sales | 4.53% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | 611.3% | ||
| Profit Quality | N/A | ||
| Current Ratio | 2.72 | ||
| Quick Ratio | 2.44 | ||
| Altman-Z | 2.96 |
F-Score4
WACC8.09%
ROIC/WACCN/A
Cap/Depr(3y)84.38%
Cap/Depr(5y)130.41%
Cap/Sales(3y)7.28%
Cap/Sales(5y)12.95%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-354.7%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%52.38%
EPS Next Y87.09%
EPS Next 2Y43.47%
EPS Next 3Y30.54%
EPS Next 5Y21.5%
Revenue 1Y (TTM)14.47%
Revenue growth 3Y16.01%
Revenue growth 5Y25.78%
Sales Q2Q%20.05%
Revenue Next Year17.56%
Revenue Next 2Y15.52%
Revenue Next 3Y14.38%
Revenue Next 5Y11.01%
EBIT growth 1Y25.75%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year328.14%
EBIT Next 3Y82.51%
EBIT Next 5Y52.71%
FCF growth 1Y1146.96%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y179.09%
OCF growth 3YN/A
OCF growth 5YN/A
EXACT SCIENCES CORP / EXAS FAQ
What is the fundamental rating for EXAS stock?
ChartMill assigns a fundamental rating of 4 / 10 to EXAS.
Can you provide the valuation status for EXACT SCIENCES CORP?
ChartMill assigns a valuation rating of 4 / 10 to EXACT SCIENCES CORP (EXAS). This can be considered as Fairly Valued.
How profitable is EXACT SCIENCES CORP (EXAS) stock?
EXACT SCIENCES CORP (EXAS) has a profitability rating of 2 / 10.